According to Illumina's latest financial reports the company has a price-to-book ratio of 4.63.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2022-12-31 | 4.82 | -12.95% |
2021-12-31 | 5.54 | -51.89% |
2020-12-31 | 11.5 | 8.86% |
2019-12-31 | 10.6 | -7.81% |
2018-12-31 | 11.5 | -1.18% |
2017-12-31 | 11.6 | 40.06% |
2016-12-31 | 8.29 | -45.5% |
2015-12-31 | 15.2 | -16.12% |
2014-12-31 | 18.1 | 96.72% |
2013-12-31 | 9.21 | 76.31% |
2012-12-31 | 5.23 | 51.79% |
2011-12-31 | 3.44 | -47.94% |
2010-12-31 | 6.61 | 48.92% |
2009-12-31 | 4.44 | 16.91% |
2008-12-31 | 3.80 | -52.36% |
2007-12-31 | 7.97 | 7.07% |
2006-12-31 | 7.45 | -7.27% |
2005-12-31 | 8.03 | 60.59% |
2004-12-31 | 5.00 | 2.22% |
2003-12-31 | 4.89 | 220.49% |
2002-12-31 | 1.53 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
![]() Thermo Fisher Scientific TMO | 4.74 | 2.56% | ๐บ๐ธ USA |
![]() Agilent Technologies A | 6.33 | 36.94% | ๐บ๐ธ USA |
![]() Quest Diagnostics
DGX | 2.43 | -47.46% | ๐บ๐ธ USA |
![]() Danaher DHR | 3.33 | -28.04% | ๐บ๐ธ USA |
![]() PerkinElmer
PKI | 1.96 | -57.67% | ๐บ๐ธ USA |
![]() Pacific Biosciences
PACB | 4.51 | -2.51% | ๐บ๐ธ USA |